medigraphic.com
Organo Oficial de la Sociedad Mexicana de Urología

2025, Number 1

<< Back

Rev Mex Urol 2025; 85 (1)

Urachal adenocarcinoma. Case report

Pesqueira VMG, Estrada GVH, Montero SON, Torres GJ, Ibarra AAP, Salas Veloz AA, Navarro GR

Language: Spanish
References: 18
Page: 1-10
PDF size: 349.05 Kb.


ABSTRACT

Description: we present a 58-year-old man who came to the emergency room complaining of macroscopic hematuria. As a result of the diagnostic protocol, an extra-bladder tumor. A wide en bloc resection of the umbilical scar, middle umbilical ligament and bladder dome was performed. Diagnosis of poorly differentiated carcinoma of the peribladder soft tissues (urachus), T3 according to Sheldon’s classification, surgical margins free of lesion, angiolymphatic invasion present. At 48-month follow-up, the patient remains negative for recurrence or metastasis.
Relevance: it is important to know the topic and make a differential diagnosis in patients who present with hematuria, as well as collaborate to compile evidence from similar clinical cases, in this way obtain greater knowledge of risk factors, with the subsequent preparation of detection protocols.
Clinical implications: urachal tumors constitute less than 1 % of bladder neoplasms, being a pathology of limited knowledge. A clinical case of urachal adenocarcinoma is presented, to provide evidence to the literature.
Conclusions: the diagnosis of urachal adenocarcinoma is rarely considered in a patient with hematuria, and although its prevalence is low, it is important to promptly identify the disease to avoid complications and morbidity and mortality in our patients.


REFERENCES

  1. Cruz P, Ramírez M, Iborra I, Rubio J, PintoF, Gómez-Ferrer A, et al. Adenocarcinoma deuraco: ¿qué tanto sabemos? Revista Mexicanade Urología. 2014;74(5): 301–307. https://doi.org/10.1016/j.uromx.2014.09.002.

  2. Quan J, Pan X, Jin L, He T, Hu J, Shi B, et al.Urachal carcinoma: Report of two cases andreview of the literature. Molecular and ClinicalOncology. 2017;6(1): 101–104. https://doi.org/10.3892/mco.2016.1082.

  3. Szarvas T, Módos O, Niedworok C, Reis H,Szendröi A, Szász MA, et al. Clinical, prognostic,and therapeutic aspects of urachal carcinoma-Acomprehensive review with meta-analysis of1,010 cases. Urologic Oncology. 2016;34(9):388–398. https://doi.org/10.1016/j.urolonc.2016.04.012.

  4. Bruins HM, Visser O, Ploeg M, Hulsbergenvande Kaa CA, Kiemeney LALM, Witjes JA.The clinical epidemiology of urachal carcinoma:results of a large, population based study. TheJournal of Urology. 2012;188(4): 1102–1107.https://doi.org/10.1016/j.juro.2012.06.020.

  5. Ashley RA, Inman BA, Sebo TJ, LeibovichBC, Blute ML, Kwon ED, et al. Urachalcarcinoma: clinicopathologic features and longtermoutcomes of an aggressive malignancy.Cancer. 2006;107(4): 712–720. https://doi.org/10.1002/cncr.22060.

  6. García Salazar N, Pérez Silva MM, AcuñaHernández M, García Salazar N, Pérez SilvaMM, Acuña Hernández M. Carcinoma deuraco, una neoplasia maligna poco frecuente.Revista Médica del Uruguay. 2018;34(1): 124–133. https://doi.org/10.29193/rmu.34.1.6.

  7. Siefker-Radtke A. Urachal carcinoma: Surgicaland chemotherapeutic options. Expert reviewof anticancer therapy. 2006;6(12): 1715–1721.https://doi.org/10.1586/14737140.6.12.1715.

  8. Zeman M, Silver E, Akin EA. CT and PETfindings for urachal adenocarcinoma: a casereport. Annals of Clinical Case Reports. 2017;2.https://hsrc.himmelfarb.gwu.edu/smhs_rad_facpubs/216/

  9. Gopalan A, Sharp DS, Fine SW, Tickoo SK,Herr HW, Reuter VE, et al. Urachal carcinoma:a clinicopathologic analysis of 24 cases withoutcome correlation. The American Journalof Surgical Pathology. 2009;33(5): 659–668.https://doi.org/10.1097/PAS.0b013e31819aa4ae.

  10. Sheldon CA, Clayman RV, Gonzalez R, WilliamsRD, Fraley EE. Malignant urachal lesions. TheJournal of Urology. 1984;131(1): 1–8. https://doi.org/10.1016/s0022-5347(17)50167-6.

  11. Herr HW, Bochner BH, Sharp D, Dalbagni G,Reuter VE. Urachal carcinoma: contemporarysurgical outcomes. The Journal of Urology.2007;178(1): 74–78; discussion 78. https://doi.org/10.1016/j.juro.2007.03.022.

  12. Limonnik V, Samiei A, Abel S, Wegner RE,Vemana G, Mao SS. Urachal carcinoma: A novelstaging system utilizing the National CancerDatabase. Cancer Medicine. 2023;12(3): 2752–2760. https://doi.org/10.1002/cam4.5164.

  13. Pinthus JH, Haddad R, Trachtenberg J,Holowaty E, Bowler J, Herzenberg AM, etal. Population based survival data on urachaltumors. The Journal of Urology. 2006;175(6):2042–2047; discussion 2047. https://doi.org/10.1016/S0022-5347(06)00263-1.

  14. Mylonas KS, O Malley P, Ziogas IA, El-KababL, Nasioudis D. Malignant urachal neoplasms: Apopulation-based study and systematic reviewof literature. Urologic Oncology. 2017;35(1):33.e11-33.e19. https://doi.org/10.1016/j.urolonc.2016.07.021.

  15. Yu YD, Ko YH, Kim JW, Jung SI, Kang SH, ParkJ, et al. The Prognosis and Oncological Predictorof Urachal Carcinoma of the Bladder: A LargeScale Multicenter Cohort Study Analyzed 203Patients With Long Term Follow-Up. Frontiersin Oncology. 2021;11. https://doi.org/10.3389/fonc.2021.683190.

  16. Song SH, Lee J, Ko YH, Kim JW, Jung SI, KangSH, et al. TNM-Based Head-to-Head Comparisonof Urachal Carcinoma and Urothelial BladderCancer: Stage-Matched Analysis of a LargeMulticenter National Cohort. Cancer Researchand Treatment : Official Journal of Korean CancerAssociation. 2023;55(4): 1337–1345. https://doi.org/10.4143/crt.2023.417.

  17. Siefker-Radtke A. Urachal adenocarcinoma:a clinician’s guide for treatment. Seminars inOncology. 2012;39(5): 619–624. https://doi.org/10.1053/j.seminoncol.2012.08.011.

  18. Ke C, Xu L, Wang M, Wang Y, ZhouQ, Chen J, et al. Treatment options andprognostic risk factors for urachal carcinoma:A multicetnter retrospective study. UrologicOncology. 2023;41(1): 50.e1-50.e9. https://doi.org/10.1016/j.urolonc.2022.09.017.




2020     |     www.medigraphic.com